Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lyme disease in Immune-Suppressed patients under investigation

NCT ID NCT07343089

First seen Jan 25, 2026 · Last updated Jun 22, 2026 · Updated 30 times

Summary

This study looks at cases of severe Lyme disease (disseminated borreliosis) in patients who have received anti-CD20 therapy, a type of immune-suppressing treatment. Researchers want to describe the symptoms, severity, and progression of the infection in these patients. The study will include up to 100 people in France who had confirmed Lyme disease within 24 months of receiving anti-CD20 treatment between 2010 and 2025.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORRELIA INFECTIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Laboratoire de Bactériologie - CHU de Strasbourg - France

    RECRUITING

    Strasbourg, 67091, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

Borrelia infectious disease Lyme disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.